Novartis announces FDA approval for Jadenu EP News Bureau Mar 31, 2015 To simplify treatment administration for patients with chronic iron overload
GSK agrees UK deal for meningitis shot after Novartis stand-off EP News Bureau Mar 30, 2015 Britain will become the first country in the world to have a nationwide vaccination programme for the potentially deadly childhood…
Big Pharma drives innovation in pain therapy development, despite declining patent applications EP News Bureau Mar 23, 2015 Patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck…
Novartis completes series of transactions with GlaxoSmithKline EP News Bureau Mar 20, 2015 Acquires certain oncology products and pipeline compounds from GSK
Fortune announces list of 2015 ‘World’s Most Admired Companies’ Usha Sharma Feb 24, 2015 Fortune magazine has announced its list of 2015 'World’s Most Admired Companies.' The companies on the world’s most admired list…
GlaxoSmithKline Pharmaceuticals announces Q4 results Usha Sharma Feb 19, 2015 Net sales of the pharmaceuticals business grew by 1.2 per cent during the quarter ended December 31, 2014
Novartis India reports loss for the quarter ended 31 December 2014 Usha Sharma Feb 5, 2015 During the quarter under review, profit before tax was Rs 4.4 crore as against Rs 21.6 crore in the previous corresponding period…
Frost & Sullivan releases drug launch and Phase III trial watch list for top therapeutic areas Usha Sharma Jan 20, 2015 Oncology, autoimmune and infectious diseases/vaccines are areas for novel therapeutics and in vitro diagnostics in 2015
Novartis Cosentyx’s first IL-17 inhibitor to receive EU approval Usha Sharma Jan 19, 2015 Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative…
Novartis approves transfer of its OTC division to GSK for Rs 1097.3 million Usha Sharma Jan 14, 2015 Novartis has approved the sale of its OTC Division to GlaxoSmithKline Consumer for Rs 1097.3 million. It may be noted that as part…